https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Products / Services / Pipelines & Platforms
TAHO Pharmaceuticals is dedicated to transforming drug delivery with innovation and care. We create advanced formulations that improve administration, safety, and efficacy of existing drugs—enhancing patients’ quality of life. Our lead asset, TAH3311—the first and only oral dissolving film (ODF) for novel oral anticoagulants—is set for FDA/EMA NDA filing. TAH4411, an Ondansetron ODF, is approved in Japan. Other assets include TAH3341 (extended-release Apixaban ODF), TAH2231 (opioid overdose antidote), TAH2211 (addiction therapy), TAH9901 and TAH9922 (ADHD therapies).
TAHO provides specialized drug delivery solutions through our Transepithelial Delivery System (TDS). We develop transdermal patches and transmucosal films to improve medication administration. Our services include formulation development and partnership support, delivering value and innovation to global pharma collaborators across three continents.
TAHO’s TDS platform drives innovation in transdermal and transmucosal delivery, enhancing lives with compassion. Our diverse pipeline includes: TAH3311: The world’s first anticoagulant Apixaban ODF TAH3341: Next generation TAH3311, extended-release Apixaban ODF TAH2231: Naloxone buccal film for opioid overdose TAH4411: Ondansetron ODF for chemo-induced nausea/vomiting TAH2211: Buprenorphine/Naloxone sublingual film for opioid addiction TAH9901: Methylphenidate patch for ADHD TAH9922: Atomoxetine liquid for ADHD
Business Interests
Out-Licensing, CDMO, Co-Development, Strategic Alliance
Contact Info
Paul Chang
BD Manager
+886-2-26598515 #2003
paulchang@tahopharma.com